GQ1033 / GeneQuantum Healthcare - LARVOL DELTA

Novel EGFR x cMET bispecific ADC GQ1033 and DLL3-ADC GQ1030 demonstrated promising therapeutic efficacy in preclinical studies (AACR 2025) - "Using the platforms, we created a broad ADC library targeting EGFR x cMET and DLL3, combining antibodies with various formats, different linkers, and payloads like MMAE, Eribulin, Exatecan, Lurbinectedin, and TopoIx...In an osimertinib-resistant NSCLC PDX trial, involving ~10 models with diverse EGFR/cMET expression levels, GQ1033 demonstrated robust antitumor activity with an overall ORR of ~70%... GQ1033 and GQ1030, developed through high-throughput screening leveraging our iGDC™ and iLDC™ platforms, have demonstrated encouraging efficacy in preclinical studies, suggesting a broader therapeutic index. These next-gen ADCs hold potential as innovative treatments for lung cancers."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • DLL3 • EGFR